AstraZeneca announced a strategic research cooperation with CSPC Group Co., Ltd. The two sides will focus on high-priority targets and cooperate to promote the discovery and development of novel oral drug candidates. These drugs are expected to treat diseases with multiple indications. Under the agreement, AstraZeneca and CSPC agreed to discover and develop preclinical drug candidates with potential for treating various chronic diseases for multiple targets, including a preclinical small molecule oral therapy for immune diseases.

Zhitongcaijing · 06/13 08:49
AstraZeneca announced a strategic research cooperation with CSPC Group Co., Ltd. The two sides will focus on high-priority targets and cooperate to promote the discovery and development of novel oral drug candidates. These drugs are expected to treat diseases with multiple indications. Under the agreement, AstraZeneca and CSPC agreed to discover and develop preclinical drug candidates with potential for treating various chronic diseases for multiple targets, including a preclinical small molecule oral therapy for immune diseases.